Imitrex
(Sumatriptan)ApprovedBiologic
Sumatriptan is used to treat migraine headaches by narrowing blood vessels around the brain and reducing substances in the body that can cause headaches, nausea, sensitivity to light and sound, and other migraine symptoms.[2] Imitrex is currently approved and in use across 11 indications[4].[1]
Imitrex is one of 220 biologic programs targeting Migraine With Aura. It is currently in Approved.
11
Indications
48
Total Trials
2
Active Trials
219
Competitors
9
FDA Applications
NDA/BLA/ANDA regulatory filings
36
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
190 competitors in Obesity
#DrugCompanyPhaseTrials
1Imitrex
GGlaxo Dba Glaxosmithkline
Approved
Synthroid
IInstitut Jerome Lejeune
Phase 3
Vivia
SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Zenagamtide
Novo NordiskPhase 3
Berobenatide
PfizerPhase 3
Eloralintide
Eli LillyPhase 3
Mibavademab
RegeneronPhase 3
Ribupatide
KKailera
Phase 3
Avapro
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Migraine14 trials
Show 11 more trials
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01986088·1,008 enrolled
Headache11 trials
Mirtazapine vs Sumatriptan in the Treatment of Postdural Puncture Headache
Completed·—·Phase 4·NCT05108688·210 enrolled
Show 8 more trials
Oral2 trials
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 3·NCT01986270·1,141 enrolled
Fed2 trials
Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions
Completed·—·Phase 1·NCT01269281·50 enrolled
16 more indications
Cesarean Section1 trial
Postoperative Quality of Recovery1 trial
Blood Pressure1 trial
ALD1 trial
Single Dose1 trial
Lactating Women on Select DOI1 trial
Unspecified2 trials
Sumatriptan and Glucose
Unknown status·—·Phase 1·NCT04690270·12 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 28, 1992
IMITREX
NDA NDA020080
Jun 1, 1995
IMITREX
NDA NDA020132
Aug 26, 1997
IMITREX
NDA NDA020626
Jun 29, 2010
ALSUMA
NDA NDA022377
Jan 17, 2013
ZECUITY
NDA NDA202278
Nov 26, 2013
SUMAVEL DOSEPRO
NDA NDA022239
Jan 27, 2016
ONZETRA XSAIL
NDA NDA206099
Jan 28, 2016
ZEMBRACE SYMTOUCH
NDA NDA208223
Jan 25, 2019
TOSYMRA
NDA NDA210884
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Imitrex drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Sumatriptan. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 1b (5-Ht1b) Receptor Agonist; Serotonin 1d (5-Ht1d) Receptor Agonist[3]
- Modality
- Biologic[3]
- Highest Phase
- Approved[1]
- Company
- GGlaxo Dba Glaxosmithkline
Patent Landscape[6]
Patent Cliff
Nov 22, 2026
Earliest patent expiration — generic entry possible after this date
Patent #Expires
11571531Feb 23, 2026
9283280May 9, 2026
8440631May 9, 2026
8268791May 9, 2026
7901385Jul 31, 2026
31 more patents
7776007Nov 22, 2026
10124132Mar 6, 2027
8470853Apr 12, 2027
8597272Apr 12, 2027
9427578Apr 12, 2027
8155737Apr 12, 2027
7973058Apr 12, 2027
7811254Aug 26, 2027
9272137Sep 7, 2027
10398859Dec 19, 2027
8875704Apr 7, 2028
10722667Dec 30, 2028
8366600Apr 21, 2029
10076615Jul 30, 2029
8550073Oct 22, 2029
10603305Jun 16, 2030
9974770Jun 16, 2030
11337962Jun 16, 2030
9610280Jun 16, 2030
12090139Jun 16, 2030
8899229Aug 18, 2030
9649456Oct 21, 2030
8983594Nov 19, 2030
8978647Dec 6, 2030
9211282Jul 19, 2031
9327114Oct 8, 2032
10478574Nov 4, 2033
10076614Oct 20, 2034
12097183Jan 29, 2036
10537554Jan 29, 2036
11364224Jan 29, 2036